Tag - NXL

Developments

Three peer-reviewed studies reveal Nexalin’s DIFS potential in AD

Nexalin Technology (NASDAQ: NXL) has announced that three independently published, peer-reviewed clinical studies collectively demonstrate the ability of its proprietary 15 mA Gen-2 Nexalin DIFS technology to improve...

October 21, 2025

Developments

USPTO grants Nexalin patent for next-gen HALO Clarity device

Nexalin Technology (NASDAQ: NXL; NXLIW) has announced that the United States Patent and Trademark Office (USPTO) has issued a design patent providing 15 years of protection for the company’s next-generation HALO Clarity...

September 25, 2025

Tag - NXL

Three peer-reviewed studies reveal Nexalin’s DIFS potential in AD

USPTO grants Nexalin patent for next-gen HALO Clarity device

Subscribe